Dynamic reciprocal interactions between activated T cells and tumor associated macrophages drive macrophage

Erika Heninger1, Matthew Thomas Breneman1, Emma Elizabeth Recchia1

  • 1Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.

Scientific Reports
|October 16, 2024
PubMed

Insights

Activated T cells can reprogram immunosuppressive tumor-associated macrophages (TAMs) in prostate cancer models. This reprogramming supports restoring anti-tumor T cell responses within the tumor microenvironment (TME).

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment (TME) and are often implicated in suppressing effective T cell responses in prostate cancer.
  • Understanding the dynamic interactions between immune cells within the prostate TME is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

  • To investigate the interactions between prostate tumor cells, macrophages, and T cells using a novel microscale cell culture platform.
  • To determine if activated T cells can reprogram immunosuppressive TAMs in the context of prostate cancer models.

Main Methods:

  • Utilized a novel microscale cell culture platform (Stacks) to create mono-, co-, and tri-culture models of the prostate TME.
  • Models included prostate tumor cell lines, primary macrophages, and autologous T cells from prostate cancer patients.
  • Employed multiplexed analysis to capture dynamic cellular interactions.

Main Results:

  • Observed a dynamic interaction between primary TAMs and activated T cells in multi-cellular prostate tumor models.
  • Demonstrated reciprocal proinflammatory activation of both TAMs and T cells upon interaction.
  • Showcased the ability of activated T cells to reprogram immunosuppressive TAMs.

Conclusions:

  • Activated T cells can reprogram immunosuppressive TAMs within prostate tumor models.
  • TAM reprogramming by T cells may play a supportive role in restoring proinflammatory T cell responses against prostate tumors.
  • These findings highlight a potential therapeutic strategy targeting TAM reprogramming in prostate cancer.